148 related articles for article (PubMed ID: 34822188)
1. Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia.
Farrukh F; Guglielmelli P; Loscocco GG; Pardanani A; Hanson CA; De Stefano V; Barbui T; Gangat N; Vannucchi AM; Tefferi A
Am J Hematol; 2022 Feb; 97(2):E35-E37. PubMed ID: 34822188
[No Abstract] [Full Text] [Related]
2. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
3. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
4. High red blood cell distribution width might predict thrombosis in essential thrombocythemia and polycythemia vera.
Krečak I; Krečak F; Gverić-Krečak V
Blood Cells Mol Dis; 2020 Feb; 80():102368. PubMed ID: 31669934
[No Abstract] [Full Text] [Related]
5. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
[No Abstract] [Full Text] [Related]
6. Glycated hemoglobin (HbA1c) and thrombotic risk in polycythemia vera and essential thrombocythemia.
Krecak I; Lekovic D; Grohovac D; Sabljic A; Holik H; Zekanovic I; Moric Peric M; Galusic D; Perisa V; Krecak F; Skelin M; Lucijanic M
Leuk Lymphoma; 2024 May; 65(5):688-691. PubMed ID: 38248137
[No Abstract] [Full Text] [Related]
7. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
Am J Hematol; 2010 Feb; 85(2):97-100. PubMed ID: 20052743
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.
Falanga A; Marchetti M; Barbui T; Smith CW
Semin Hematol; 2005 Oct; 42(4):239-47. PubMed ID: 16210037
[TBL] [Abstract][Full Text] [Related]
9. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.
Barbui T; Carobbio A; Finazzi G; Vannucchi AM; Barosi G; Antonioli E; Guglielmelli P; Pancrazzi A; Salmoiraghi S; Zilio P; Ottomano C; Marchioli R; Cuccovillo I; Bottazzi B; Mantovani A; Rambaldi A;
Haematologica; 2011 Feb; 96(2):315-8. PubMed ID: 21173097
[TBL] [Abstract][Full Text] [Related]
10. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
Vannucchi AM; Antonioli E; Guglielmelli P; Rambaldi A; Barosi G; Marchioli R; Marfisi RM; Finazzi G; Guerini V; Fabris F; Randi ML; De Stefano V; Caberlon S; Tafuri A; Ruggeri M; Specchia G; Liso V; Rossi E; Pogliani E; Gugliotta L; Bosi A; Barbui T
Blood; 2007 Aug; 110(3):840-6. PubMed ID: 17379742
[TBL] [Abstract][Full Text] [Related]
11. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.
Coucelo M; Caetano G; Sevivas T; Almeida Santos S; Fidalgo T; Bento C; Fortuna M; Duarte M; Menezes C; Ribeiro ML
Int J Hematol; 2014 Jan; 99(1):32-40. PubMed ID: 24277659
[TBL] [Abstract][Full Text] [Related]
12. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
Barbui T; Carobbio A; Rambaldi A; Finazzi G
Blood; 2009 Jul; 114(4):759-63. PubMed ID: 19372254
[TBL] [Abstract][Full Text] [Related]
14. Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Landolfi R; Di Gennaro L
Haematologica; 2008 Mar; 93(3):331-5. PubMed ID: 18310537
[No Abstract] [Full Text] [Related]
15. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.
Kamiunten A; Shide K; Kameda T; Sekine M; Kubuki Y; Ito M; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Akizuki K; Tahira Y; Shimoda H; Hidaka T; Yamashita K; Matsuoka H; Shimoda K
Int J Hematol; 2018 Jun; 107(6):681-688. PubMed ID: 29488167
[TBL] [Abstract][Full Text] [Related]
16. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.
Trifa AP; Cucuianu A; Popp RA; Coadă CA; Costache RM; Militaru MS; Vesa ŞC; Pop IV
Ann Hematol; 2014 Feb; 93(2):203-9. PubMed ID: 23828072
[TBL] [Abstract][Full Text] [Related]
17. Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC; Gómez M
Eur J Haematol; 2015 Jan; 94(1):4-11. PubMed ID: 24814134
[TBL] [Abstract][Full Text] [Related]
18. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.
Mora B; Giorgino T; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Cavalloni C; Barraco D; Pietra D; Barbui T; Rotunno G; Vannucchi AM; Passamonti F
Leuk Res; 2018 Jun; 69():100-102. PubMed ID: 29734070
[No Abstract] [Full Text] [Related]
19. Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis.
Iland HJ; Laszlo J; Case DC; Murphy S; Reichert TA; Tso CY; Wasserman LR
Am J Hematol; 1987 Jun; 25(2):191-201. PubMed ID: 3605067
[TBL] [Abstract][Full Text] [Related]
20. Increased Lipocalin 2 level may have important role in thrombotic events in patients with polycythemia vera and essential thrombocythemia.
Rajnics P; Kellner Á; Karádi É; Moizs M; Bödör C; Király PA; Marosvári D; Andrikovics H; Egyed M
Leuk Res; 2016 Sep; 48():101-6. PubMed ID: 27161323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
